1. Home
  2. /
  3. Projects
  4. /
  5. Page 2

research

The potential health and economic impact of introducing the vaccine candidate VPM1002 to prevent tuberculosis disease in low- and middle-income countries

This study estimates the potential health and economic impact of introducing the TB vaccine candidate VPM1002 in 79 low- and middle- income countries. It models routine vaccination and vaccination campaigns, estimating TB cases and deaths averted and the cost-effectiveness of different introduction scenarios. It provides evidence for decisions about the potential future introduction and scale-up of VPM1002

Advancing evidence-informed in-country decision-making for new TB vaccine introduction: A responsive and integrated vaccine modelling approach from India

As new TB vaccines move into late-stage development, it is imperative for high-burden countries like India to ensure timely and effective evidence-generation to inform decision-making and accelerate vaccine development and introduction. To enable this, an in-country vaccine mathematical modelling effort has been initiated in India.

The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries

Estimates the potential economic impact of introducing novel TB vaccines in 105 low- and middle- income countries. It compares ifnant and adolescents/ adult vaccination scenarios and models their effects on TB- related mortality, morbidity, healthcare costs and GDP. Finding support decision making on the future development and introduciton of novel TB vaccines

TBVacMod

Estimate the health impact of introducing a prevention of disease vaccine for adult and adolescents in moderate to high TB burden countries. Explore different vaccine introduction scenarios based on input from country stakeholders, including national TB program and immunization program officials, on priority groups for vaccination and likely vaccine coverage. The project's key questions include: 1) who are the priority groups in different countries and what is expected level of vaccine coverage in those groups 2) how will vaccine impact differ in different introduction scenarios (vary age, priority group, coverage)
Click to copy link of this header Menu